Resumen:
font face="AdvTT7b8c60ca.B" size="1">
In the present work, we investigated a first generation of a new dendrimer as candidate for intravenous (iv) administration of a therapeutic compound (2(-(benzo[1,2-c] 1,2,5-oxadiazol-5(6)-yl (N-1-oxide) methylidene]-1-methoxy methane hydrazide). This compound presents antichagasic activity bu